HuR mediates the synergistic effects of angiotensin II and IL-1β on vascular COX-2 expression and cell migration

British Journal of Pharmacology

Volumn 172, Issue 12, 2015, Pages 3028-3042

  Aguado, A ^a   Rodriguez C ^b   Martinez Revelles S ^a   Avendano M S ^a   Zhenyukh, O ^a   Orriols, M ^b   Martinez Gonzalez J ^b   Alonso, M J ^c   Briones, A M ^a   Dixon, D A ^d   Salaices, M ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b Institut Català de Ciències Cardiovasculars   (Spain)

^c UNIVERSIDAD REY JUAN CARLOS   (Spain)

^d UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 ACETYL 2 (8 CHLORO 10,11 DIHYDRODIBENZ[B,F][1,4]OXAZEPINE 10 CARBONYL)HYDRAZINE; 1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 MORPHOLINO 8 PHENYLCHROMONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ANGIOTENSIN II; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; CELECOXIB; CYCLOOXYGENASE 2; FUREGRELATE; HUR PROTEIN; INTERLEUKIN 1BETA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; N [(5 BROMO 2 METHOXYPHENYL)SULFONYL] 3 [2 (2 NAPHTHYLMETHYL)PHENYL]ACRYLAMIDE; OZAGREL; PHOSPHATIDYLINOSITOL 3 KINASE; PROSTACYCLIN SYNTHASE; PROSTAGLANDIN E RECEPTOR; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE; PROSTANOID; PROTEIN KINASE B; STRESS ACTIVATED PROTEIN KINASE; TENASCIN; THROMBOXANE RECEPTOR; THROMBOXANE SYNTHASE; ELAV LIKE PROTEIN 1; MESSENGER RNA;

3' UNTRANSLATED REGION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTICLE; CELL MIGRATION; CELL MIGRATION ASSAY; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DRUG MECHANISM; EMBRYO; ENZYME ACTIVATION; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; LEFT COMMON CAROTID ARTERY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN LOCALIZATION; PROTEIN PROCESSING; PROTEIN RNA BINDING; PROTEIN TRANSPORT; RAT; RNA STABILITY; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; UPREGULATION; VASCULAR REMODELING; VASCULAR SMOOTH MUSCLE CELL; ANIMAL; C57BL MOUSE; CELL MOTION; CYTOLOGY; DRUG EFFECTS; DRUG POTENTIATION; GENETICS; METABOLISM; MOUSE; PHYSIOLOGY; SPRAGUE DAWLEY RAT; VASCULAR SMOOTH MUSCLE;

ANGIOTENSIN II; ANIMALS; AORTA; CELECOXIB; CELL MOVEMENT; CYCLOOXYGENASE 2; DRUG SYNERGISM; ELAV-LIKE PROTEIN 1; GENE EXPRESSION REGULATION; HUMANS; INTERLEUKIN-1BETA; MALE; MICE; MICE, INBRED C57BL; MUSCLE, SMOOTH, VASCULAR; RATS; RATS, SPRAGUE-DAWLEY; RNA STABILITY; RNA, MESSENGER; TENASCIN; VASCULAR REMODELING;

EID: 84930226318     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.13103     Document Type: Article

References (46)

1. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013a). The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors. Br J Pharmacol 170: 1459-1581.
2. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013b). The Concise Guide to PHARMACOLOGY 2013/14: Catalytic receptors. Br J Pharmacol 170: 1676-1705.
3. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013c). The Concise Guide to PHARMACOLOGY 2013/14: Enzymes. Br J Pharmacol 170: 1797-1867.
4. Abdelmohsen K, Gorospe M, (2010). Posttranscriptional regulation of cancer traits by HuR. Wiley Interdiscip Rev RNA 1: 214-229.
5. Aguado A, Galán M, Zhenyukh O, Wiggers GA, Roque FR, Redondo S, et al. (2013). Mercury induces proliferation and reduces cell size in vascular smooth muscle cells through MAPK, oxidative stress and cyclooxygenase-2 pathways. Toxicol Appl Pharmacol 268: 188-200.
6. Aotani Y, Saitoh Y, (1995). Structure determination of MS-444; a new myosin light chain kinase inhibitor. J Antibiot (Tokyo) 48: 952-953.
7. Avendaño MS, Lucas E, Jurado-Pueyo M, Martínez-Revelles S, Vila-Bedmar R, Mayor F Jr, et al. (2014). Increased nitric oxide bioavailability in adult GRK2 hemizygous mice protects against angiotensin II-induced hypertension. Hypertension 63: 369-375.
8. Bos CL, Richel DJ, Ritsema T, Peppelenbosch MP, Versteeg HH, (2004). Prostanoids and prostanoid receptors in signal transduction. Int J Biochem Biol 36: 1187-1205.
9. Cipollone F, Fazia ML, (2006). COX-2 and atherosclerosis. J Cardiovasc Pharmacol 47 (Suppl. 1): S26-S36.
10. Dange RB, Agarwal D, Masson GS, Vila J, Wilson B, Nair A, et al. (2014). Central blockade of TLR4 improves cardiac function and attenuates myocardial inflammation in angiotensin II-induced hypertension. Cardiovasc Res 103: 17-27.
11. Dixon DA, Kaplan CD, McIntyre TM, Zimmerman GA, Prescott SM, (2000). Post-transcriptional control of cyclooxygenase-2 gene expression. The role of the 3′-untranslated region. J Biol Chem 275: 11750-11757.
12. Dixon DA, Tolley ND, King PH, Nabors LB, McIntyre TM, Zimmerman GA, et al. (2001). Altered expression of the mRNA stability factor HuR promotes cyclooxygenase-2 expression in colon cancer cells. J Clin Invest 108: 1657-1665.
13. Dixon DA, Tolley ND, Bemis-Standoli K, Martinez ML, Weyrich AS, Morrow JD, et al. (2006). Expression of COX-2 in platelet-monocyte interactions occurs via combinatorial regulation involving adhesion and cytokine signaling. J Clin Invest 116: 2727-2738.
14. Doller A, Akool E-S, Huwiler A, Müller R, Radeke HH, Pfeilschifter J, et al. (2008). Posttranslational modification of the AU-rich element binding protein HuR by protein kinase Cdelta elicits angiotensin II-induced stabilization and nuclear export of cyclooxygenase 2 mRNA. Mol Cell Biol 28: 2608-2625.
15. Facemire CS, Griffiths R, Audoly LP, Koller BH, Coffman TM, (2010). The impact of microsomal prostaglandin E synthase 1 on blood pressure is determined by genetic background. Hypertension 55: 531-538.
16. Galán M, Miguel M, Beltrán AE, Rodríguez C, García-Redondo AB, Rodríguez-Calvo R, et al. (2011). Angiotensin II differentially modulates cyclooxygenase-2, microsomal prostaglandin E2 synthase-1 and prostaglandin I2 synthase expression in adventitial fibroblasts exposed to inflammatory stimuli. J Hypertens 29: 529-536.
17. Han C, Michalopoulos GK, Wu T, (2006). Prostaglandin E2 receptor EP1 transactivates EGFR/MET receptor tyrosine kinases and enhances invasiveness in human hepatocellular carcinoma cells. J Cell Physiol 207: 261-270.
18. Harper KA, Tyson-Capper AJ, (2008). Complexity of COX-2 gene regulation. Biochem Soc Trans 36 (Pt 3): 543-545.
19. Huang C, Jacobson K, Schaller MD, (2004). MAP kinases and cell migration. J Cell Sci 117 (Pt 20): 4619-4628.
20. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). Animal research: Reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160: 1577-1579.
21. Lal A, Mazan-Mamczarz K, Kawai T, Yang X, Martindale JL, Gorospe M, (2004). Concurrent versus individual binding of HuR and AUF1 to common labile target mRNAs. EMBO J 23: 3092-3102.
22. Marchesi C, Paradis P, Schiffrin EL, (2008). Role of the renin-angiotensin system in vascular inflammation. Trends Pharmacol Sci 29: 367-374.
23. Martín A, Perez-Girõn JV, Hernanz R, Palacios R, Briones AM, Fortuño A, et al. (2012). Peroxisome proliferator-activated receptor-γ activation reduces cyclooxygenase-2 expression in vascular smooth muscle cells from hypertensive rats by interfering with oxidative stress. J Hypertens 30: 315-326.
24. Martínez-Revelles S, Avendaño MS, García-Redondo AB, Álvarez Y, Aguado A, Pérez-Girõn JV, et al. (2013). Reciprocal relationship between reactive oxygen species and cyclooxygenase-2 and vascular dysfunction in hypertension. Antioxid Redox Signal 18: 51-65.
25. McGrath J, Drummond G, McLachlan E, Kilkenny C, Wainwright C, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
26. Meisner NC, Filipowicz W, (2011). Properties of the regulatory RNA-binding protein HuR and its role in controlling miRNA repression. Adv Exp Med Biol 700: 106-123.
27. Mugabe BE, Yaghini FA, Song CY, Buharalioglu CK, Waters CM, Malik KU, (2010). Angiotensin II-induced migration of vascular smooth muscle cells is mediated by p38 mitogen-activated protein kinase-activated c-Src through spleen tyrosine kinase and epidermal growth factor receptor transactivation. J Pharmacol Exp Ther 332: 116-124.
28. Nie D, Lamberti M, Zacharek A, Li L, Szekeres K, Tang K, et al. (2000). Thromboxane A(2) regulation of endothelial cell migration, angiogenesis, and tumor metastasis. Biochem Biophys Res Commun 267: 245-251.
29. Ohnaka K, Numaguchi K, Yamakawa T, Inagami T, (2000). Induction of cyclooxygenase-2 by angiotensin II in cultured rat vascular smooth muscle cells. Hypertension 35: 68-75.
30. Orriols M, Guadall A, Galán A, Martí-Pàmies I, Varona S, Rodríguez-Calvo R, et al. (2014). Lysyl oxidase (LOX) in vascular remodelling: insight from a new animal model. Thromb Haemost 112: 812-824.
31. Patrignani P, Patrono C, (2015). Cyclooxygenase inhibitors: from pharmacology to clinical read-outs. Biochim Biophys Acta 181: 422-432.
32. Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, Buneman OP, et al.; NC-IUPHAR (2014). The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledgebase of drug targets and their ligands. Nucl. Acids Res 42 (Database Issue): D1098-D1106.
33. Pham H, Chong B, Vincenti R, Slice LW, (2008). Ang II and EGF synergistically induce COX-2 expression via CREB in intestinal epithelial cells. J Cell Physiol 214: 96-109.
34. Pullmann R Jr, Juhaszova M, Lõpez de Silanes I, Kawai T, Mazan-Mamczarz K, Halushka MK, et al. (2005). Enhanced proliferation of cultured human vascular smooth muscle cells linked to increased function of RNA-binding protein HuR. J Biol Chem 280: 22819-22826.
35. Rodríguez-Calvo R, Guadall A, Calvayrac O, Navarro MA, Alonso J, Ferrán B, et al. (2013). Over-expression of neuron-derived orphan receptor-1 (NOR-1) exacerbates neointimal hyperplasia after vascular injury. Hum Mol Genet 22: 1949-1959.
36. Scott JA, Xie L, Li H, Li W, He JB, Sanders PN, et al. (2012). The multifunctional Ca2+/calmodulin-dependent kinase II regulates vascular smooth muscle migration through matrix metalloproteinase 9. Am J Physiol Heart Circ Physiol 302: H1953-H1964.
37. Sparks MA, Makhanova NA, Griffiths RC, Snouwaert JN, Koller BH, Coffman TM, (2013). Thromboxane receptors in smooth muscle promote hypertension, vascular remodeling, and sudden death. Hypertension 6: 166-173.
38. Uchiyama K, Saito M, Sasaki M, Obara Y, Higashiyama S, Nakahata N, (2009). Thromboxane A2 receptor-mediated epidermal growth factor receptor transactivation: involvement of PKC-delta and PKC-epsilon in the shedding of epidermal growth factor receptor ligands. Eur J Pharm Sci 38: 504-511.
39. Wang M, Ihida-Stansbury K, Kothapalli D, Tamby MC, Yu Z, Chen L, et al. (2011). Microsomal prostaglandin E2 synthase-1 modulates the response to vascular injury. Circulation 123: 631-639.
40. Woodhoo A, Iruarrizaga-Lejarreta M, Beraza N, García-Rodríguez JL, Embade N, Fernández-Ramos D, et al. (2012). Human antigen R contributes to hepatic stellate cell activation and liver fibrosis. Hepatology 56: 1870-1882.
41. Yamaoka K, Yano A, Kuroiwa K, Morimoto K, Inazumi T, Hatae N, et al. (2009). Prostaglandin EP3 receptor superactivates adenylyl cyclase via the Gq/PLC/Ca2+ pathway in a lipid raft-dependent manner. Biochem Biophys Res Commun 389: 678-682.
42. Yang HM, Kim HS, Park KW, You HJ, Jeon SI, Youn SW, et al. (2004). Celecoxib, a cyclooxygenase-2 inhibitor, reduces neointimal hyperplasia through inhibition of Akt signaling. Circulation 110: 301-308.
43. Yang X, Wang W, Fan J, Lal A, Yang D, Cheng H, et al. (2004). Prostaglandin A2-mediated stabilization of p21 mRNA through an ERK-dependent pathway requiring the RNA-binding protein HuR. J Biol Chem 279: 49298-49306.
44. Young LE, Moore AE, Sokol L, Meisner-Kober N, Dixon DA, (2012). The mRNA stability factor HuR inhibits microRNA-16 targeting of COX-2. Mol Cancer Res 10: 167-180.
45. Yu Z, Ricciotti E, Miwa T, Liu S, Ihida-Stansbury K, Landersberg G, et al. (2013). Myeloid cell 5-lipoxygenase activating protein modulates the response to vascular injury. Circ Res 112: 432-440.
46. Zhang J, Zou F, Tang J, Zhang Q, Gong Y, Wang Q, et al. (2013). Cyclooxygenase-2-derived prostaglandin E2 promotes injury-induced vascular neointimal hyperplasia through the E-prostanoid 3 receptor. Circ Res 113: 104-114.